Skip to content

Pioneering Methods in Brain Optimization and Mental Health Treatment.

Robert B. Kargbo

ACS Medicinal Chemistry Letters March 14, 2024 DOI: 10.1021/acsmedchemlett.4c00058 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Interventions AI-driven non-invasive neurostimulation N-isopropyl tryptamines tryptamine derivatives psilocybin psilocin
Keywords Psychedelics Artificial intelligence Brain stimulation Mental health
Key findings AI-driven non-invasive neurostimulation and tryptamine derivatives show promise for personalized brain therapy and mental health treatment.

Abstract

This Patent Highlight explores ground-breaking advancements in neurostimulation, psychedelic therapy, and brain function optimization from recent innovations. It examines methods for altering brain states through AI-driven non-invasive neurostimulation, potentially contributing to personalized brain therapy. The publication also delves into the therapeutic potential of N-isopropyl tryptamines and tryptamine derivatives. Furthermore, it discusses the therapeutic applications of psilocybin and psilocin crystalline forms in mental health and central nervous system disorders. By comparing and contrasting these diverse approaches, this work highlights their mechanistic insights, therapeutic implications, and contributions to the evolving fields of neuroscience and mental health.